Active clinical trials for "Urinary Bladder, Overactive"

To evaluate the efficacy and the safety of KUC-7483 in overactive bladder patients.

To assess the long term safety, tolerability and efficacy of fesoterodine in patients with OAB.

The purpose of this study is to compare the difference between tolterodine prolonged release (PR) and propiverine in efficacy as assessed by the AUM and to show that tolterodine PR is similar to propiverine with respect to micturition chart variables and safety profile.

The purpose of the study is to evaluate the effect of YM178 in patients with overactive bladder for 12-week administration.

This study is designed to investigate whether a new drug may offer safe and effective treatment for patients with overactive bladder.

This Phase 3B study is designed to test if a fesoterodine flexible dose regimen is more effective than placebo in reducing micturition frequency and other overactive bladder (OAB) symptoms, e.g., urgency, urgency incontinence episodes in patients with overactive bladder and if the fesoterodine regimen is safe and well tolerated.

To evaluate the efficacy and safety of fesoterodine in comparison to placebo for overactive bladder.

To evaluate the efficacy and safety of fesoterodine on overactive bladder symptom improvement when added to ongoing alpha blocker treatment.

The purpose of this study is to assess the safety and effectiveness of botulinum toxin type A in treating overactive bladder in spinal cord injury or multiple sclerosis patients

To evaluate the effect of fesoterodine on patient satisfaction and overactive bladder (OAB) symptom relief in OAB patients who were dissatisfied with their prior therapy with tolterodine.